Ken J. Ishii
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 202 publications
STING agonists as next-generation vaccine adjuvants: mechanisms, opportunities, and challenges.
Journal: Current opinion in virology
Published: January 16, 2026
IL-1 delineates squalene-based adjuvant efficacy and reactogenicity in a cell-type-specific manner.
Journal: NPJ vaccines
Published: November 03, 2025
Gut Microbiota-Derived Bacterial Extracellular Vesicles in COVID-19: Their Signature and Immunological Impact.
Journal: Journal of extracellular vesicles
Published: October 31, 2025
Efficacy of intranasal adenovirus vector vaccine is attenuated by type I IFN-induced NK cell activation.
Journal: Molecular therapy. Advances
Published: September 18, 2025
HLA-B*15:01-positive severe COVID-19 patients lack CD8+ T cell pools with highly expanded public clonotypes.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 02, 2025
Enhancement of Immune Modulation by Toll-Like Receptor 9 Adjuvant Combination Subcutaneous Immunotherapy for Japanese Cedar Pollinosis.
Journal: Biological & pharmaceutical bulletin
Published: August 12, 2025
OTUD3 prevents ulcerative colitis by inhibiting microbiota-mediated STING activation.
Journal: Science immunology
Published: July 18, 2025
Resident alveolar macrophages are highly susceptible to the induction of RIPK1/RIPK3-mediated necroptosis which promote efficient pulmonary immune response.
Journal: Cell death & disease
Published: July 14, 2025
Vaccine adjuvants as stand-alone immunoprophylaxis in strategies for 100-day rapid responses to future pandemics.
Journal: International immunology
Published: July 09, 2025
Last Updated: 09/26/2026